Skip NavigationSkip to Content

Arl2-Mediated Allosteric Release of Farnesylated KRas4B from Shuttling Factor PDE delta

  1. Author:
    Ozdemir, E. Sila
    Jang, Hyunbum
    Gursoy, Attila
    Keskin, Ozlem
    Nussinov, Ruth
  2. Author Address

    Koc Univ, Dept Chem & Biol Engn, TR-34450 Istanbul, Turkey.Koc Univ, Dept Comp Engn, TR-34450 Istanbul, Turkey.Koc Univ, Res Ctr Translat Med, TR-34450 Istanbul, Turkey.Leidos Biomed Res Inc, Canc & Inflammat Program, Frederick Natl Lab Canc Res, NCI, Ft Detrick, MD 21702 USA.Tel Aviv Univ, Sakler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel.
    1. Year: 2018
    2. Date: Aug 2
  1. Journal: JOURNAL OF PHYSICAL CHEMISTRY B
  2. AMER CHEMICAL SOC,
    1. 122
    2. 30
    3. Pages: 7503-7513
  3. Type of Article: Article
  4. ISSN: 1520-6106
  1. Abstract:

    Proper localization of Ras proteins at the plasma membrane (PM) is crucial for their functions. To get to the PM, KRas4B and some other Ras family proteins bind to the PDE delta shuttling protein through their farnesylated hypervariable regions (HVRs). The docking of their famesyl (and to a lesser extent geranylgeranyl) in the hydrophobic pocket of PDE delta's stabilizes the interaction. At the PM, guanosine 5'-triphosphate (GTP)-bound Arf-like protein 2 (Arl2) assists in the release of Ras from the PDE delta. However, exactly how is still unclear. Using all-atom molecular dynamics simulations, we unraveled the detailed mechanism of Arl2-mediated release of KRas4B, the most abundant oncogenic Ras isoform, from PDE delta. We simulated ternary Arl2 PDE delta KRas4B HVR complexes and observed that Arl2 binding weakens the PDE delta farnesylated HVR interaction. Our detailed analysis showed that allosteric changes (involving beta 6 of PDE delta and additional PDE delta residues) compress the hydrophobic PDE delta pocket and push the HVR out. Mutating PDE delta residues that mediate allosteric changes in PDE delta terminates the release process. Mutant Ras proteins are enriched in human cancers, with currently no drugs in the clinics. This mechanistic account may inspire efforts to develop drugs suppressing oncogenic KRas4B release.

    See More

External Sources

  1. DOI: 10.1021/acs.jpcb.8b04347
  2. PMID: 29961325
  3. WOS: 000440956300005

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel